Ignite Creation Date:
2024-05-05 @ 11:57 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01455389
Status:
TERMINATED
Last Update Posted:
2022-03-02
First Post:
2011-10-17
Brief Title:
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Sponsor:
Genprex Inc
Organization:
Genprex Inc
Organization Data
Organization:
Genprex Inc
Class:
INDUSTRY
Study ID:
ONC-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Genprex Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None